Grey Wolf Therapeutics, an Oxford, UK-based clinical-stage biotechnology company leveraging antigen modulation therapies, raised $50M in Series B extension funding.
The round, which brought the total amount to $99M, was led by ICG’s Life Sciences team and included participation from existing investors Pfizer Ventures, Andera Partners, Canaan, Earlybird Venture Capital, Oxford Science Enterprises and British Patient Capital.
The company intends to use the funds to broaden the scope of its ongoing Phase 1/2 clinical trial of its lead immuno-oncology candidate, GRWD5769, in a range of solid tumour types and to expand its research and development (R&D) for its versatile antigen modulation approach into treatments for autoimmune disease indications.
Led by CEO Peter Joyce, Grey Wolf Therapeutics is a clinical-stage drug discovery and development biotechnology company providing a therapeutic approach based on an antigen modulation platform. Its lead clinical development candidate, GRWD5769, is a potent and selective oral ERAP1 inhibitor that has shown the potential to elicit a differentiated immune response against tumours. A second ERAP1 inhibitor, GRWD0715, is advancing through preclinical development as a potential treatment for autoimmune disease. The company is also leveraging its leadership in neoantigen creation with an ERAP2 drug discovery program and by therapeutically targeting novel ERAP1 inhibitor generated cancer antigens with MHC Class I directed therapies, such as soluble T cell receptor (TCR) and TCR mimic bispecifics.
FinSMEs
23/05/2024